军医进修学院学报2011，Vol.32Issue(6)：568-570,3.DOI:CNKI:11-3275/R.20101230.0949.000
吉西他滨联合顺铂治疗蒽环类及紫杉类耐药性晚期乳腺癌疗效观察
Curative effect of combined gemcitabine and cisplatin on anthracycline and taxane-resistant advanced breast cancer
谢文秀 1李自健 2游俊浩 3张帆 3杨俊兰3
作者信息
- 1. 海军总医院特需医疗部,北京100048
- 2. 武汉161医院肿瘤科,武汉430010
- 3. 解放军总医院肿瘤科,北京100853
- 折叠
摘要
Abstract
To observe the curative effect and safety of combined gemcitabine and cisplatin for anthracycline and taxaneresistant advanced breast cancer(ABC) patients. Methods Sixty anthracycline and taxane-resistant ABC patients admitted to Chinese PLA General Hospital from October 2004 to July 2009 were treated with gemcitabine(1000-1250mg/m2) on days 1 and 8 and cisplatin(25mg/m2) on days 1-3 by intravenous drip after admission, 21 days as a cycle. Curative effect of chemotherapy was evaluated after 2 cycles of treatment. Side effects of chemotherapy were monitored. Results The 60 patients received 3.7 cycles (range 2-6) of chemotherapy. Of the 60 patients, 1(1.7%) showed a complete response, 19(31.7%) a partial response, 30(50.0%) a stable disease, and 10(16.7%) a progressive disease. The overall response rate was 33.4%. The median progression time of the disease was 4.2 months and the overall survival time of the patients was 18.3 months. The major side effects of chemotherapy were bone marrow inhibition and gastrointestinal reactions. Conclusion Combined gemcitabine and cisplatin therapy is effective and safe for anthracycline and taxane-resistant ABC patients.关键词
乳腺肿瘤/化疗/吉西他滨/顺铂Key words
Breast Neoplasms/Chemotherapy/Gemcitabine/Cisplatin分类
基础医学引用本文复制引用
谢文秀,李自健,游俊浩,张帆,杨俊兰..吉西他滨联合顺铂治疗蒽环类及紫杉类耐药性晚期乳腺癌疗效观察[J].军医进修学院学报,2011,32(6):568-570,3.
